RVMD - Amgen Lumakras combination data in lung cancer held until August - Reuters

• Data on Amgen's Lumakras (sotorasib) in combination with Merck's ( NYSE: MRK ) Keytruda (pembrolizumab) and Roche's ( OTCQX:RHHBY ) Tecentriq (atezoliuzumab) will be released on Aug. 7 instead of this month, Reuters reported.
• Results will be released at the 2022 World Conference on Lung Cancer.
• Conference organizers released data Tuesday from a small trial of Lumakras combined with RMC-4630 from Revolution Medicine ( RVMD ) and Sanofi ( SNY ). The trial enrolled 11 patients with severe non-small cell lung cancer (NSCLC). Results showed three patients had tumor shrinkage and seven had stable disease.
• Lumakras was approved in 2021 under the U.S. FDA's Accelerated Approval program as a second-line NSCLC treatment. Amgen ( NASDAQ: AMGN ) is eying further indications of the drug in earlier stages of lung cancer.
• The drug may eventually compete with Mirati Therapeutics' ( NASDAQ: MRTX ) experimental adagrasib, which like Lumakras, is a KRAS inhibitor. Adagrasib is also under investigation for colorectal cancer .
• Lumakras annual revenues could reach $1.5B by 2026-2027 , according to Seeking Alpha contributor Natalie Koo.

For further details see: